What Comes Next for Eli Lilly?
Eli Lilly & Co. announced that its experimental Alzheimer's treatment, Solanezumab, failed in a final-stage trial. Bloomberg Intelligence's Sam Fazeli and Vamil Divan, analyst at Credit Suisse, examine Eli Lilly's path forward with this drug and others in its pipeline. They speak on "Bloomberg Markets." Divan, his family, and firm do not own shares of Eli Lilly & Co., but his firm supplies the company with public offering services as an investment banking client, as well as investment banking services. (Source: Bloomberg)
Most Recent Videos
How Bannon's Ouster May Impact Trump's Agenda
21:58 - Stephen Bannon will leave his role as chief strategist to President Donald Trump, with today being his last day in the White House. Bloomberg's Sahil Kapur and Craig Gordon examine what’s next for the Trump Administration on "Bloomberg Markets: The Trump Economy." (Source: Bloomberg)